{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:10:07Z","timestamp":1792606207264,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303886"],"award-info":[{"award-number":["82303886"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072025"],"award-info":[{"award-number":["82072025"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072026"],"award-info":[{"award-number":["82072026"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The outcome of hepatocellular carcinoma (HCC) is limited by its complex molecular characteristics and changeable tumor microenvironment (TME). Here we focused on elucidating the functional consequences of Maternal embryonic leucine zipper kinase (MELK) in the tumorigenesis, progression and metastasis of HCC, and exploring the effect of MELK on immune cell regulation in the TME, meanwhile clarifying the corresponding signaling networks.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Bioinformatic analysis was used to validate the prognostic value of MELK for HCC. Murine xenograft assays and HCC lung metastasis mouse model confirmed the role of MELK in tumorigenesis and metastasis in HCC. Luciferase assays, RNA sequencing, immunopurification\u2013mass spectrometry (IP-MS) and coimmunoprecipitation (CoIP) were applied to explore the upstream regulators, downstream essential molecules and corresponding mechanisms of MELK in HCC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We confirmed MELK to be a reliable prognostic factor of HCC and identified MELK as an effective candidate in facilitating the tumorigenesis, progression, and metastasis of HCC; the effects of MELK depended on the targeted regulation of the upstream factor miR-505-3p and interaction with STAT3, which induced STAT3 phosphorylation and increased the expression of its target gene CCL2 in HCC. In addition, we confirmed that tumor cell-intrinsic MELK inhibition is beneficial in stimulating M1 macrophage polarization, hindering M2 macrophage polarization and inducing CD8\u2009+\u2009T-cell recruitment, which are dependent on the alteration of CCL2 expression. Importantly, MELK inhibition amplified RT-related immune effects, thereby synergizing with RT to exert substantial antitumor effects. OTS167, an inhibitor of MELK, was also proven to effectively impair the growth and progression of HCC and exert a superior antitumor effect in combination with radiotherapy (RT).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Altogether, our findings highlight the functional role of MELK as a promising target in molecular therapy and in the combination of RT therapy to improve antitumor effect for HCC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12943-024-02049-0","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T07:01:49Z","timestamp":1720162909000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Tumor cell-intrinsic MELK enhanced CCL2-dependent immunosuppression to exacerbate hepatocarcinogenesis and confer resistance of HCC to radiotherapy"],"prefix":"10.1186","volume":"23","author":[{"given":"Bufu","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueli","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiji","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongfang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoyou","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfei","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiansong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"issue":"3","key":"2049_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"issue":"10","key":"2049_CR2","first-page":"599","volume":"15","author":"JM Llovet","year":"2018","unstructured":"Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma, Nature reviews. Clin Oncol. 2018;15(10):599\u2013616.","journal-title":"Clin Oncol"},{"issue":"1","key":"2049_CR3","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1016\/S0168-8278(12)60009-9","volume":"56","author":"CR de Lope","year":"2012","unstructured":"de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol. 2012;56(1):S75\u201387.","journal-title":"J Hepatol"},{"issue":"1","key":"2049_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jhep.2011.07.007","volume":"56","author":"JU Marquardt","year":"2012","unstructured":"Marquardt JU, Galle PR, Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J Hepatol. 2012;56(1):267\u201375.","journal-title":"J Hepatol"},{"issue":"5","key":"2049_CR5","first-page":"1522","volume":"10","author":"D Kong","year":"2020","unstructured":"Kong D, Liu C, Miao X, Wang Y, Ding X, Gong W. Current statuses of molecular targeted and immune checkpoint therapies in hepatocellular carcinoma. Am J cancer Res. 2020;10(5):1522\u201333.","journal-title":"Am J cancer Res"},{"issue":"21","key":"2049_CR6","doi-asserted-by":"publisher","first-page":"9751","DOI":"10.1158\/0008-5472.CAN-04-4531","volume":"65","author":"D Gray","year":"2005","unstructured":"Gray D, Jubb AM, Hogue D, Dowd P, Kljavin N, Yi S, Bai W, Frantz G, Zhang Z, Koeppen H, de Sauvage FJ, Davis DP. Maternal embryonic leucine zipper kinase\/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. Cancer Res. 2005;65(21):9751\u201361.","journal-title":"Cancer Res"},{"issue":"1","key":"2049_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41392-020-00288-3","volume":"5","author":"Q Tang","year":"2020","unstructured":"Tang Q, Li W, Zheng X, Ren L, Liu J, Li S, Wang J, Du G. MELK is an oncogenic kinase essential for metastasis, mitotic progression, and programmed death in lung carcinoma. Signal Transduct Target Therapy. 2020;5(1):279.","journal-title":"Signal Transduct Target Therapy"},{"issue":"4","key":"2049_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41419-022-04827-4","volume":"13","author":"B Tang","year":"2022","unstructured":"Tang B, Zhu J, Liu F, Ding J, Wang Y, Fang S, Zheng L, Qiu R, Chen M, Shu G, Xu M, Lu C, Zhao Z, Yang Y, Ji J. xCT contributes to colorectal cancer tumorigenesis through upregulation of the MELK oncogene and activation of the AKT\/mTOR cascade. Cell Death Dis. 2022;13(4):373.","journal-title":"Cell Death Dis"},{"issue":"23","key":"2049_CR9","doi-asserted-by":"publisher","first-page":"5864","DOI":"10.1158\/1078-0432.CCR-15-2711","volume":"22","author":"C Speers","year":"2016","unstructured":"Speers C, Zhao SG, Kothari V, Santola A, Liu M, Wilder-Romans K, Evans J, Batra N, Bartelink H, Hayes DF, Lawrence TS, Brown PH, Pierce LJ, Feng FY. Maternal embryonic leucine Zipper kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in human breast Cancer. Clin cancer Research: Official J Am Association Cancer Res. 2016;22(23):5864\u201375.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"1","key":"2049_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.canlet.2016.09.017","volume":"383","author":"H Xia","year":"2016","unstructured":"Xia H, Kong SN, Chen J, Shi M, Sekar K, Seshachalam VP, Rajasekaran M, Goh BKP, Ooi LL, Hui KM. MELK is an oncogenic kinase essential for early hepatocellular carcinoma recurrence. Cancer Lett. 2016;383(1):85\u201393.","journal-title":"Cancer Lett"},{"issue":"16","key":"2049_CR11","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC. The tumor microenvironment. Curr Biology: CB. 2020;30(16):R921\u20135.","journal-title":"Curr Biology: CB"},{"issue":"1","key":"2049_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","volume":"30","author":"I Vitale","year":"2019","unstructured":"Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the Tumor Microenvironment. Cell Metabol. 2019;30(1):36\u201350.","journal-title":"Cell Metabol"},{"issue":"11","key":"2049_CR13","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1172\/JCI87252","volume":"126","author":"M Yin","year":"2016","unstructured":"Yin M, Li X, Tan S, Zhou HJ, Ji W, Bellone S, Xu X, Zhang H, Santin AD, Lou G, Min W. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J Clin Investig. 2016;126(11):4157\u201373.","journal-title":"J Clin Investig"},{"key":"2049_CR14","first-page":"e2203973","volume-title":"Targeted xCT-mediated ferroptosis and Protumoral polarization of Macrophages is effective against HCC and enhances the efficacy of the Anti-PD-1\/L1 response, Advanced science","author":"B Tang","year":"2022","unstructured":"Tang B, Zhu J, Wang Y, Chen W, Fang S, Mao W, Xu Z, Yang Y, Weng Q, Zhao Z, Chen M, Ji J. Targeted xCT-mediated ferroptosis and Protumoral polarization of Macrophages is effective against HCC and enhances the efficacy of the Anti-PD-1\/L1 response, Advanced science. Baden-Wurttemberg, Germany): Weinheim; 2022. p. e2203973."},{"key":"2049_CR15","doi-asserted-by":"publisher","first-page":"824938","DOI":"10.3389\/fcell.2022.824938","volume":"10","author":"Y Liu","year":"2022","unstructured":"Liu Y, Li R, Wang X, Xue Z, Yang X, Tang B. Comprehensive analyses of MELK-Associated ceRNA Networks reveal a potential biomarker for Predicting Poor Prognosis and Immunotherapy Efficacy in Hepatocellular Carcinoma. Front cell Dev Biology. 2022;10:824938.","journal-title":"Front cell Dev Biology"},{"key":"2049_CR16","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.freeradbiomed.2021.06.012","volume":"172","author":"B Tang","year":"2021","unstructured":"Tang B, Zhu J, Fang S, Wang Y, Vinothkumar R, Li M, Weng Q, Zheng L, Yang Y, Qiu R, Xu M, Zhao Z, Ji J. Pharmacological inhibition of MELK restricts ferroptosis and the inflammatory response in colitis and colitis-propelled carcinogenesis. Free Radic Biol Med. 2021;172:312\u201329.","journal-title":"Free Radic Biol Med"},{"key":"2049_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.radonc.2020.03.027","volume":"148","author":"CH Rim","year":"2020","unstructured":"Rim CH, Cheng J, Huang WY, Kimura T, Lee V, Zeng ZC, Seong J. An evaluation of hepatocellular carcinoma practice guidelines from a radiation oncology perspective. Radiotherapy Oncology: J Eur Soc Therapeutic Radiol Oncol. 2020;148:73\u201381.","journal-title":"Radiotherapy Oncology: J Eur Soc Therapeutic Radiol Oncol"},{"issue":"5","key":"2049_CR18","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.ijrobp.2021.12.162","volume":"112","author":"SS Du","year":"2022","unstructured":"Du SS, Chen GW, Yang P, Chen YX, Hu Y, Zhao QQ, Zhang Y, Liu R, Zheng DX, Zhou J, Fan J, Zeng ZC. Radiation Therapy promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING activation. Int J Radiat Oncol Biol Phys. 2022;112(5):1243\u201355.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2049_CR19","first-page":"313","volume":"18","author":"W Ngwa","year":"2018","unstructured":"Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. Using immunotherapy to boost the abscopal effect, Nature reviews. Cancer. 2018;18(5):313\u201322.","journal-title":"Cancer"},{"issue":"2","key":"2049_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Investig. 2014;124(2):687\u201395.","journal-title":"J Clin Investig"},{"issue":"5","key":"2049_CR21","first-page":"870","volume":"31","author":"C Gu","year":"2013","unstructured":"Gu C, Banasavadi-Siddegowda YK, Joshi K, Nakamura Y, Kurt H, Gupta S, Nakano I. Tumor-specific activation of the C-JUN\/MELK pathway regulates glioma stem cell growth in a p53-dependent manner, stem cells (Dayton. Ohio). 2013;31(5):870\u201381.","journal-title":"Ohio)"},{"key":"2049_CR22","doi-asserted-by":"crossref","unstructured":"Beke L, Kig C, Linders JTM, Boens S, Boeckx A, van Heerde E, Parade M, De Bondt A, Van den Wyngaert I, Bashir T, Ogata S, Meerpoel L, Van Eynde A, Johnson CN, Beullens M, Brehmer D, Bollen M. Correction: MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells. Biosci Rep 38(6) (2018).","DOI":"10.1042\/BSR-20150194_COR"},{"issue":"10","key":"2049_CR23","doi-asserted-by":"publisher","first-page":"14433","DOI":"10.18632\/aging.203059","volume":"13","author":"D Chen","year":"2021","unstructured":"Chen D, Yan Y, Wang X, Li S, Liu Y, Yu D, He Y, Deng R, Liu Y, Xu M, Luo J, Gao H, Wang S. Chronic alcohol exposure promotes HCC stemness and metastasis through \u03b2-catenin\/miR-22-3p\/TET2 axis. Aging. 2021;13(10):14433\u201355.","journal-title":"Aging"},{"issue":"3","key":"2049_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41419-018-0287-5","volume":"9","author":"R Jin","year":"2018","unstructured":"Jin R, Lin H, Li G, Xu J, Shi L, Chang C, Cai X. TR(4) nuclear receptor suppresses HCC cell invasion via downregulating the EphA2 expression. Cell Death Dis. 2018;9(3):283.","journal-title":"Cell Death Dis"},{"issue":"10","key":"2049_CR25","first-page":"1447","volume":"32","author":"S Dogan","year":"2019","unstructured":"Dogan S, Vasudevaraja V, Xu B, Serrano J, Ptashkin RN, Jung HJ, Chiang S, Jungbluth AA, Cohen MA, Ganly I, Berger MF, Momeni Boroujeni A, Ghossein RA, Ladanyi M, Chute DJ, Snuderl M. DNA methylation-based classification of sinonasal undifferentiated carcinoma, modern pathology: an official journal of the United States and Canadian Academy of Pathology. Inc. 2019;32(10):1447\u201359.","journal-title":"Inc"},{"key":"2049_CR26","doi-asserted-by":"publisher","first-page":"216021","DOI":"10.1016\/j.canlet.2022.216021","volume":"554","author":"B Tang","year":"2022","unstructured":"Tang B, Wang Y, Xu W, Zhu J, Weng Q, Chen W, Fang S, Yang Y, Qiu R, Chen M, Mao W, Xu M, Zhao Z, Cai S, Zhang H, Ji J. Macrophage xCT deficiency drives immune activation and boosts responses to immune checkpoint blockade in lung cancer. Cancer Lett. 2022;554:216021.","journal-title":"Cancer Lett"},{"key":"2049_CR27","doi-asserted-by":"crossref","unstructured":"Huang S. mTOR Signaling in Metabolism and Cancer. Cells 9(10) (2020).","DOI":"10.3390\/cells9102278"},{"issue":"4","key":"2049_CR28","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ccell.2018.07.009","volume":"34","author":"O Meurette","year":"2018","unstructured":"Meurette O, Mehlen P. Notch Signaling in the Tumor Microenvironment. Cancer Cell. 2018;34(4):536\u201348.","journal-title":"Cancer Cell"},{"key":"2049_CR29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.phrs.2016.02.028","volume":"111","author":"S Wang","year":"2016","unstructured":"Wang S, Dougherty EJ, Danner RL. PPAR\u03b3 signaling and emerging opportunities for improved therapeutics. Pharmacol Res. 2016;111:76\u201385.","journal-title":"Pharmacol Res"},{"issue":"4","key":"2049_CR30","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.cell.2009.02.005","volume":"136","author":"A Ventura","year":"2009","unstructured":"Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell. 2009;136(4):586\u201391.","journal-title":"Cell"},{"key":"2049_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","volume":"387","author":"T Wu","year":"2017","unstructured":"Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2017;387:61\u20138.","journal-title":"Cancer Lett"},{"key":"2049_CR32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-012418-012718","volume":"15","author":"M Locati","year":"2020","unstructured":"Locati M, Curtale G, Mantovani A. Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol. 2020;15:123\u201347.","journal-title":"Annu Rev Pathol"},{"key":"2049_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane M, Baba H, Lenz HJ. CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat Rev. 2018;63:40\u20137.","journal-title":"Cancer Treat Rev"},{"key":"2049_CR34","doi-asserted-by":"crossref","unstructured":"Kim SH, Joshi K, Ezhilarasan R, Myers TR, Siu J, Gu C, Nakano-Okuno M, Taylor D, Minata M, Sulman EP, Lee J, Bhat KP, Salcini AE, Nakano I. EZH2 protects glioma stem cells from radiation-induced cell death in a MELK\/FOXM1-dependent manner. Stem cell Rep 4(2) (2015) 226\u2009\u2013\u200938.","DOI":"10.1016\/j.stemcr.2014.12.006"},{"issue":"10","key":"2049_CR35","first-page":"589","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management, Nature reviews. Gastroenterol Hepatol. 2019;16(10):589\u2013604.","journal-title":"Gastroenterol Hepatol"},{"issue":"8","key":"2049_CR36","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1158\/1078-0432.CCR-13-0547","volume":"20","author":"JM Llovet","year":"2014","unstructured":"Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin cancer Research: Official J Am Association Cancer Res. 2014;20(8):2072\u20139.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"6","key":"2049_CR37","first-page":"340","volume":"11","author":"T Shibata","year":"2014","unstructured":"Shibata T, Aburatani H. Exploration of liver cancer genomes, Nature reviews. Gastroenterol Hepatol. 2014;11(6):340\u20139.","journal-title":"Gastroenterol Hepatol"},{"key":"2049_CR38","doi-asserted-by":"publisher","first-page":"102609","DOI":"10.1016\/j.ebiom.2019.102609","volume":"51","author":"Q Xu","year":"2020","unstructured":"Xu Q, Ge Q, Zhou Y, Yang B, Yang Q, Jiang S, Jiang R, Ai Z, Zhang Z, Teng Y. MELK promotes endometrial carcinoma progression via activating mTOR signaling pathway. EBioMedicine. 2020;51:102609.","journal-title":"EBioMedicine"},{"issue":"2","key":"2049_CR39","first-page":"491","volume":"39","author":"YJ Liu","year":"2018","unstructured":"Liu YJ, Li W, Chang F, Liu JN, Lin JX, Chen DX. MicroRNA-505 is downregulated in human osteosarcoma and regulates cell proliferation, migration and invasion. Oncol Rep. 2018;39(2):491\u2013500.","journal-title":"Oncol Rep"},{"key":"2049_CR40","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.biopha.2017.04.028","volume":"92","author":"C Ma","year":"2017","unstructured":"Ma C, Xu B, Husaiyin S, Wang L, Wusainahong K, Ma J, Zhu K, Niyazi M. MicroRNA-505 predicts prognosis and acts as tumor inhibitor in cervical carcinoma with inverse association with FZD4. Biomed Pharmacotherapy = Biomedecine Pharmacotherapie. 2017;92:586\u201394.","journal-title":"Biomed Pharmacotherapy = Biomedecine Pharmacotherapie"},{"key":"2049_CR41","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.3389\/fimmu.2019.02056","volume":"10","author":"MM Hanlon","year":"2019","unstructured":"Hanlon MM, Rakovich T, Cunningham CC, Ansboro S, Veale DJ, Fearon U, McGarry T. STAT3 mediates the Differential effects of Oncostatin M and TNF\u03b1 on RA synovial fibroblast and endothelial cell function. Front Immunol. 2019;10:2056.","journal-title":"Front Immunol"},{"key":"2049_CR42","doi-asserted-by":"crossref","unstructured":"de Araujo ED, Orlova A, Neubauer HA, Bajusz D, Seo HS, Dhe-Paganon S, Keser\u0171 GM, Moriggl R, Gunning PT. Structural Implications of STAT3 and STAT5 SH2 Domain Mutations, Cancers 11(11) (2019).","DOI":"10.3390\/cancers11111757"},{"key":"2049_CR43","doi-asserted-by":"publisher","first-page":"722916","DOI":"10.3389\/fonc.2021.722916","volume":"11","author":"J Jin","year":"2021","unstructured":"Jin J, Lin J, Xu A, Lou J, Qian C, Li X, Wang Y, Yu W, Tao H. CCL2: an important mediator between Tumor cells and Host Cells in Tumor Microenvironment. Front Oncol. 2021;11:722916.","journal-title":"Front Oncol"},{"key":"2049_CR44","doi-asserted-by":"crossref","unstructured":"Pozzi S, Scomparin A, Ben-Shushan D, Yeini E, Ofek P, Nahmad AD, Soffer S, Ionescu A, Ruggiero A, Barzel A, Brem H, Hyde TM, Barshack I, Sinha S, Ruppin E, Weiss T, Madi A, Perlson E, Slutsky I, Florindo HF, Satchi-Fainaro R. MCP-1\/CCR2 axis inhibition sensitizes the brain microenvironment against melanoma brain metastasis progression. JCI Insight 7(17) (2022).","DOI":"10.1172\/jci.insight.154804"},{"issue":"8","key":"2049_CR45","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41419-022-05169-x","volume":"13","author":"YF Wang","year":"2022","unstructured":"Wang YF, Yu L, Hu ZL, Fang YF, Shen YY, Song MF, Chen Y. Regulation of CCL2 by EZH2 affects tumor-associated macrophages polarization and infiltration in breast cancer. Cell Death Dis. 2022;13(8):748.","journal-title":"Cell Death Dis"},{"key":"2049_CR46","doi-asserted-by":"crossref","unstructured":"Ju M, Bi J, Wei Q, Jiang L, Guan Q, Zhang M, Song X, Chen T, Fan J, Li X, Wei M, Zhao L. Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer. Brief Bioinform 22(4) (2021).","DOI":"10.1093\/bib\/bbaa345"},{"issue":"6","key":"2049_CR47","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.apsb.2021.03.027","volume":"11","author":"Q Xie","year":"2021","unstructured":"Xie Q, Ding J, Chen Y. Role of CD8(+) T lymphocyte cells: interplay with stromal cells in tumor microenvironment. Acta Pharm Sinica B. 2021;11(6):1365\u201378.","journal-title":"Acta Pharm Sinica B"},{"issue":"1","key":"2049_CR48","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.annonc.2019.10.002","volume":"31","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, Lewis KD, Di Giacomo AM, Demidov L, Mandal\u00e0 M, Bondarenko I, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Simmons B, Ye C, Hooper G, Wongchenko MJ, Goodman GR, Yan Y, Schadendorf D. Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAF(v600) mutation-positive melanoma receiving adjuvant vemurafenib. Annals Oncology: Official J Eur Soc Med Oncol. 2020;31(1):153\u20139.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"key":"2049_CR49","doi-asserted-by":"crossref","unstructured":"Lhuillier C, Rudqvist NP, Yamazaki T, Zhang T, Charpentier M, Galluzzi L, Dephoure N, Clement CC, Santambrogio L, Zhou XK, Formenti SC, Demaria S. Radiotherapy-exposed CD8\u2009+\u2009and CD4\u2009+\u2009neoantigens enhance tumor control. J Clin Investig 131(5) (2021).","DOI":"10.1172\/JCI138740"},{"issue":"10","key":"2049_CR50","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41419-022-05319-1","volume":"13","author":"T Sun","year":"2022","unstructured":"Sun T, Li Y, Yang Y, Liu B, Cao Y, Yang W. Enhanced radiation-induced immunogenic cell death activates chimeric antigen receptor T cells by targeting CD39 against glioblastoma. Cell Death Dis. 2022;13(10):875.","journal-title":"Cell Death Dis"},{"key":"2049_CR51","doi-asserted-by":"publisher","first-page":"e26693","DOI":"10.7554\/eLife.26693","volume":"6","author":"HT Huang","year":"2017","unstructured":"Huang HT, Seo HS, Zhang T, Wang Y, Jiang B, Li Q, Buckley DL, Nabet B, Roberts JM, Paulk J, Dastjerdi S, Winter GE, McLauchlan H, Moran J, Bradner JE, Eck MJ, Dhe-Paganon S, Zhao JJ, Gray NS. MELK is not necessary for the proliferation of basal-like breast cancer cells. eLife. 2017;6:e26693.","journal-title":"eLife"},{"key":"2049_CR52","doi-asserted-by":"crossref","unstructured":"Giuliano CJ, Lin A, Smith JC, Palladino AC, Sheltzer JM. MELK expression correlates with tumor mitotic activity but is not required for cancer growth, eLife, 7 (2018) e32838.","DOI":"10.7554\/eLife.32838"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-024-02049-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-024-02049-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-024-02049-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T08:09:15Z","timestamp":1720166955000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-024-02049-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2049"],"URL":"https:\/\/doi.org\/10.1186\/s12943-024-02049-0","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,5]]},"assertion":[{"value":"22 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}